Total submissions: 1
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Ambry Genetics | RCV004167956 | SCV003662125 | uncertain significance | not specified | 2022-11-18 | criteria provided, single submitter | clinical testing | The c.339G>T (p.E113D) alteration is located in exon 2 (coding exon 1) of the B3GALT2 gene. This alteration results from a G to T substitution at nucleotide position 339, causing the glutamic acid (E) at amino acid position 113 to be replaced by an aspartic acid (D). Based on insufficient or conflicting evidence, the clinical significance of this alteration remains unclear. |